Roughly 80 or more peptide drugs have received FDA approval, with over 150 additional candidates in active clinical development as of recent counts. These drugs span an enormous range of conditions, from diabetes and obesity to cancer, hormonal disorders, and infectious disease. The landscape has shifted dramatically in just the past few years, driven largely by the explosive popularity of GLP-1 receptor agonists like semaglutide, but the peptide drug class is far broader and older than most people realize.
The Size of the Approved Peptide Drug Landscape
Counting peptide drugs precisely depends on where you draw the line between a “peptide” and a “protein.” Most pharmacologists consider anything under about 50 amino acids a peptide, though some databases stretch the definition further. One comprehensive database cataloging FDA-approved therapeutic proteins and peptides lists 85 entries specifically classified as peptides or polypeptides, alongside a much larger pool of protein therapeutics including antibodies.1PubMed. THPdb2: compilation of FDA approved therapeutic peptides and proteins Other reviews put the number of approved peptide drugs at over 60, depending on how the category is defined, with the count continuing to grow each year.2PubMed. Therapeutic peptides: Historical perspectives, current development trends, and future directions The important point is that peptide drugs are no longer a niche: they represent a well-established and expanding drug class used by tens of millions of people worldwide.
Insulin and the Drugs That Started It All
The story of peptide therapeutics begins with insulin, arguably the most consequential drug discovery of the twentieth century. Its isolation and purification in the early 1920s by Banting, Best, Macleod, and Collip was one of the first times modern medicine could offer a lifesaving therapy for a previously fatal disease.3JCI Insight. The discovery of insulin revisited: lessons for the modern era That breakthrough ushered in a century of refinement, from animal-derived insulin to recombinant human formulations and modern analogs like insulin lispro, insulin glargine, and insulin degludec, each engineered for different speed and duration profiles.4PubMed. The Discovery and Structure of Human Insulin
Oxytocin and vasopressin, both short peptide hormones, followed as early therapeutic peptides used for labor induction and blood pressure regulation, respectively. These natural hormones demonstrated the template that most peptide drugs follow: identify a signaling molecule the body already uses, then manufacture a version that can be given as a drug. The vasopressin analog desmopressin, for instance, is still widely prescribed for conditions like diabetes insipidus and bedwetting. Many of the peptide drugs in use today descend from this same logic of copying and refining naturally occurring signaling peptides.
Diabetes and Weight Management
This is the category generating the most public attention. GLP-1 receptor agonists, the drug class that includes semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza), are all peptide drugs. They mimic a natural gut hormone called glucagon-like peptide-1 that your body releases after eating. GLP-1 stimulates insulin secretion, slows stomach emptying, and acts on brain circuits that regulate appetite, which is why these drugs work for both blood sugar control and weight loss.5PubMed Central. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
The newest wave in this space involves dual-action peptides. Tirzepatide (Mounjaro, Zepbound) activates receptors for both GLP-1 and another gut hormone called GIP (glucose-dependent insulinotropic polypeptide). GIP and GLP-1 have overlapping but distinct effects: both stimulate insulin release, but they differ in how they influence fat metabolism and glucagon production. GIP directly stimulates fat storage in healthy fat tissue, while GLP-1 indirectly promotes fat breakdown. Together, the dual approach appears to produce stronger effects on both blood sugar and body weight than targeting GLP-1 alone.6PubMed Central. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Research into even more complex hybrid peptides is underway. Animal studies have shown proof-of-concept for peptide hybrids combining GLP-1 activity with amylin activity, another pancreatic hormone involved in satiety. In obese diabetic mice, these hybrids reduced blood sugar and body weight as effectively as giving two separate peptide drugs together.7PubMed Central. Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids The broader trend is clear: the metabolic peptide pipeline is moving toward multi-target molecules that pack several mechanisms into a single injection.
Other notable peptide drugs in the metabolic space include exenatide (Byetta, Bydureon), the first commercially successful GLP-1 agonist, which was originally derived from a compound found in Gila monster saliva. Pramlintide (Symlin), an analog of the pancreatic hormone amylin, is another peptide prescribed alongside insulin for people whose blood sugar remains difficult to control.
Hormonal and Reproductive Peptides
A large share of approved peptide drugs are hormone analogs used in endocrinology and reproductive medicine. These include:
- GnRH agonists and antagonists: Leuprolide (Lupron), goserelin (Zoladex), and cetrorelix (Cetrotide) manipulate the reproductive hormone axis. They are used for conditions ranging from endometriosis and uterine fibroids to prostate cancer and fertility treatments.
- Growth hormone-releasing peptides: Tesamorelin (Egrifta) stimulates the body’s own growth hormone production and is approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy. Sermorelin served a similar function for growth hormone deficiency in children, though it is no longer widely marketed.
- ACTH analogs: Cosyntropin (Cortrosyn) is a synthetic fragment of adrenocorticotropic hormone used diagnostically to test adrenal gland function.
- Calcitonin: Salmon calcitonin (Miacalcin) is a peptide used for postmenopausal osteoporosis, delivered as a nasal spray — one of the earlier examples of a non-injectable peptide drug.
- Teriparatide: A fragment of parathyroid hormone (Forteo) that stimulates new bone formation, used for severe osteoporosis.
FDA-approved peptide analogs also exist for natural hormones like somatostatin. Octreotide (Sandostatin) and lanreotide (Somatuline) are somatostatin analogs used to treat acromegaly and certain neuroendocrine tumors. These drugs illustrate a common pattern: the natural peptide hormone has a half-life of just a few minutes in the bloodstream, so chemists engineer a modified version that lasts hours or even weeks.8PubMed Central. Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms
Oncology Peptides
Peptide drugs in cancer treatment take several forms. The GnRH agonists mentioned above (leuprolide, goserelin) are among the most widely used, prescribed to suppress sex hormones that fuel hormone-sensitive cancers like prostate and breast cancer. But the oncology peptide toolkit extends beyond hormone manipulation.
Lutetium Lu-177 dotatate (Lutathera) is a radiolabeled peptide: a somatostatin analog attached to a radioactive atom. When injected, the peptide homes in on neuroendocrine tumor cells that express somatostatin receptors and delivers targeted radiation directly to the tumor. This approach, called peptide receptor radionuclide therapy, represents one of the more creative uses of peptides in medicine.
A growing area of research involves peptide-drug conjugates, or PDCs. These work on the same general principle as antibody-drug conjugates but use a small homing peptide instead of a large antibody to deliver a toxic payload to cancer cells. The advantage of the peptide approach is size: PDCs weigh roughly 1 to 3 kilodaltons compared to about 150 kilodaltons for antibody conjugates, which allows them to penetrate deeper into solid tumors and clear from the body faster.9PubMed Central. Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles PDCs are also simpler and cheaper to manufacture than antibody-based alternatives.10PubMed Central. Peptide-Drug Conjugates: A New Hope for Cancer Several are in clinical trials, though most have not yet reached approval. The field is watching closely because PDCs could bring targeted cancer therapy to tumors that antibody conjugates struggle to reach.
Antimicrobial Peptides
Antimicrobial peptides represent a class with enormous potential that has proven stubbornly difficult to translate into finished drugs. The human body naturally produces host defense peptides that kill bacteria by disrupting their cell membranes, and hundreds of similar molecules have been identified across nature. The appeal is obvious in an era of rising antibiotic resistance: these peptides use physical mechanisms to destroy bacteria that are harder for microbes to evolve resistance against compared to conventional antibiotics.11PubMed. Therapeutic potential of host defense peptides in antibiotic-resistant infections
In practice, though, most antimicrobial peptides have struggled in clinical development. They tend to be unstable in the bloodstream, can be toxic to human cells at the concentrations needed to kill bacteria, and are expensive to manufacture at scale. A handful have made it to market for topical or localized use. The broader pipeline continues to explore ways around these limitations, including engineered versions with improved stability and reduced toxicity.12PubMed. Antimicrobial peptides: Opportunities and challenges in overcoming resistance This remains one of the most active areas of peptide research, but the reader should know that the clinical reality lags well behind the laboratory promise.
Why Most Peptide Drugs Still Require Injection
The biggest practical limitation of peptide drugs is how they get into your body. Natural peptides are chewed up by enzymes throughout the digestive tract. Even if fragments survive the stomach, the intestinal wall is largely impermeable to molecules of this size. And once peptides reach the bloodstream, they are quickly filtered by the kidneys and degraded by enzymes circulating in the blood. Unmodified peptides often have plasma half-lives measured in minutes.13PubMed. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides
Drug developers use several chemical strategies to get around this. Attaching a fatty acid chain to a peptide allows it to bind to albumin, a large protein in the blood, which shields it from kidney filtration and slows its breakdown. This is the trick behind liraglutide and semaglutide, both of which are lipidated GLP-1 analogs that last long enough to be given once daily or once weekly rather than every few hours.14PubMed Central. Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives – Section: Abstract Other approaches include PEGylation (attaching polyethylene glycol chains), substituting unnatural amino acids that resist enzymatic breakdown, or cyclizing the peptide to protect its vulnerable ends.15PubMed. Strategies to improve plasma half life time of peptide and protein drugs
Despite all these modifications, the majority of approved peptide drugs are still delivered by subcutaneous injection. This is the default for insulin, GLP-1 agonists, GnRH analogs, and most others on the market. The injectable format has gotten more convenient over the decades — autoinjector pens have largely replaced syringes — but it remains a barrier for many patients.
The Push Toward Oral and Inhaled Peptide Drugs
Oral semaglutide (Rybelsus) was a landmark when it launched, because it demonstrated that a peptide drug could be taken as a pill with meaningful clinical effects. The trick is a permeation enhancer called SNAC (salcaprozate sodium) that is co-formulated with the drug. SNAC increases the fluidity of cell membranes in the stomach lining, creating a temporary window for the peptide to pass through. Even so, oral bioavailability sits at only about 1%, meaning 99% of the dose never reaches the bloodstream. The pill simply contains a much larger dose to compensate.16Molecular Pharmaceutics. Molecular Investigation of SNAC as an Oral Peptide Permeation Enhancer in Lipid Membranes via Solid-State NMR Patients must take it on an empty stomach with a small amount of water and wait at least 30 minutes before eating, because food rapidly destroys absorption.
Nasal and pulmonary routes offer other non-injectable options. Salmon calcitonin has been available as a nasal spray for decades. Inhaled insulin (Afrezza) delivers rapid-acting insulin through the lungs, taking advantage of the large surface area and thin epithelial barrier in the lower airways. The pulmonary route has attracted interest for other peptide and protein drugs as well, though the challenges of precise dosing and variable absorption based on breathing technique remain real obstacles.17PubMed Central. Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes Pulmonary delivery is being explored particularly for chronic lung diseases, where the peptide can act locally rather than needing to reach the systemic circulation.18PubMed. Protein and peptide delivery to lungs by using advanced targeted drug delivery
Macrocyclic Peptides and Oral Bioavailability
One of the more promising structural innovations involves macrocyclic peptides, which are ring-shaped molecules that bridge the gap between traditional small-molecule drugs and linear peptides. By constraining the peptide backbone into a cycle, chemists can improve metabolic stability and, in some cases, enable the molecule to cross cell membranes in ways that linear peptides cannot. Macrocyclic peptides are also attracting attention for their ability to target protein-protein interactions, a category of biological targets that traditional small-molecule drugs have historically struggled to reach. Their moderate size, high selectivity, and strong binding make them appealing candidates for drug development.19PubMed Central. Utilization of macrocyclic peptides to target protein-protein interactions in cancer
Cyclosporine, the immunosuppressant used in organ transplantation, is perhaps the best-known example of an orally bioavailable cyclic peptide, though it predates the current wave of design interest. Newer macrocyclic peptides are being designed from scratch using computational methods and high-throughput screening technologies, with oral delivery as an explicit design goal.
Manufacturing Challenges and Environmental Costs
Making peptide drugs at scale is expensive and wasteful compared to manufacturing conventional small-molecule pills. The dominant production method, solid-phase peptide synthesis, involves building the peptide chain one amino acid at a time on a solid support, with repeated cycles of chemical reactions and solvent washes. This process uses large volumes of organic solvents. On average, the process mass intensity for peptide synthesis — the total mass of materials needed per unit of product — is roughly 13,000, compared to a few hundred for typical small-molecule drugs.20PubMed Central. Process Mass Intensity (PMI): A Holistic Analysis of Current Peptide Manufacturing Processes Informs Sustainability in Peptide Synthesis In practical terms, producing one kilogram of a peptide drug can generate thousands of kilograms of waste solvent.
Recent innovations are tackling this problem. A wash-free solid-phase synthesis method demonstrated at production scale reduced total waste by about 80% for the manufacture of liraglutide, achieving the same product quality as the conventional process.21Nature Communications. Total wash elimination for solid phase peptide synthesis Recombinant production, where bacteria like E. coli are engineered to produce the peptide biologically rather than through chemical synthesis, offers another route that may be more cost-effective for longer or more complex peptides.22PubMed Central. Recombinant production of medium- to large-sized peptides in Escherichia coli using a cleavable self-aggregating tag With demand for GLP-1 drugs surging worldwide, manufacturing capacity and sustainability have become urgent industry priorities rather than academic concerns.
Immunogenicity and Safety Considerations
Peptide drugs sit in an interesting immunological middle ground. They are generally too small to trigger a strong immune response on their own, unlike large protein drugs or antibodies, which can provoke the body into producing anti-drug antibodies that neutralize the therapy. But peptides are not invisible to the immune system either. Some can act as haptens — small molecules that become immunogenic when they bind to larger proteins in the body. Etelcalcetide (Parsabiv), a peptide used for secondary hyperparathyroidism in dialysis patients, is an example that required careful immunogenicity assessment during development because its unusual D-amino acid backbone raised the possibility of hapten-like behavior.23PubMed. Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments
Manufacturing impurities also play a role. As peptide manufacturing processes become more complex, the potential for process-related impurities to affect immunogenicity risk has become a growing focus for regulators.24PubMed Central. Immunogenicity of therapeutic peptide products: bridging the gaps regarding the role of product-related risk factors This concern is especially relevant as biosimilar and generic versions of peptide drugs enter the market — slight differences in manufacturing could produce slightly different impurity profiles, with unknown immunological consequences.
Peptides Inspired by Venoms and Natural Toxins
Nature has been a productive source of peptide drug leads. Captopril, the first ACE inhibitor approved for treating high blood pressure (in 1981), was designed based on the structure of a bradykinin-potentiating peptide found in the venom of a Brazilian pit viper. The natural venom peptide was too expensive to isolate at scale and could not be taken orally, so chemists designed a miniaturized version with a chemical modification allowing oral absorption.25PubMed Central. Venom peptides – A comprehensive translational perspective in pain management – Section: Cobra venom-Captopril Captopril itself is technically a small molecule rather than a peptide drug, but the discovery pathway it pioneered — starting from a venom peptide and engineering a drug — has been repeated many times since.
Exenatide, as mentioned earlier, came from Gila monster saliva. Ziconotide (Prialt), used for severe chronic pain, is a synthetic version of a peptide found in cone snail venom. It is delivered directly into the spinal fluid because it cannot cross the blood-brain barrier on its own. These examples illustrate that the natural world contains a vast library of bioactive peptides that evolution has already optimized for potency and specificity against biological targets. Drug developers are increasingly screening venom libraries and marine organisms for new peptide leads.
Artificial Intelligence in Peptide Drug Design
The newest frontier in peptide therapeutics involves using machine learning to design peptide sequences from scratch. Generative deep learning models can be trained on databases of known bioactive peptides and then asked to produce entirely new sequences with desired properties — say, high binding affinity for a cancer-related receptor combined with resistance to enzymatic breakdown. These models can learn to assign higher probability to sequences that possess specific therapeutic characteristics, dramatically accelerating the early stages of drug discovery.26Briefings in Bioinformatics. Peptide-based drug discovery through artificial intelligence: towards an autonomous design of therapeutic peptides
The practical impact is still early-stage. AI can generate candidate sequences faster than traditional methods, but those candidates still need to be synthesized, tested for activity in cells, evaluated in animals, and eventually run through human clinical trials. No AI-designed peptide drug has yet reached the market. Still, the technology is compressing timelines in the discovery phase, and several biotech companies have built their entire pipelines around computationally designed peptides. Given the broad design space — even a short peptide of 10 amino acids has 20 to the power of 10 possible sequences — computational tools that can intelligently navigate that space rather than brute-force it represent a genuine step change in how these drugs are found.